This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
The types of resources analysed were the drugs, hospital ward stays (antenatal, labour, and post-natal) , neonatal and maternal intensive care admissions, and different modes of delivery (caesarean section, forceps, etc). The hospital costs per episode of care were adjusted for hospital occupancy rates. Data collection forms were used to elicit the resource use from the nine trial hospitals, as well as by face-to-face interviews with clinicians and midwives. The unit costs were from national sources, such as Department of Health Reference Costs, or provided by the trial participating hospitals, while the drug manufacturer (Serono) provided the progesterone costs. The costs of resources were averaged across all trial participants and reported in UK pounds sterling (£). The price year was 2008. Independent sample t-tests were used to assess group differences in resource use and costs, followed by bias-corrected bootstrapping to address skewness.
Analysis of uncertainty:
The overall uncertainty in the costs and effects was tested by creating a sampling distribution, using bootstrap statistics. The results of the bootstrapped analyses were presented in a cost-effectiveness acceptability curve and on the costeffectiveness plane. One-way sensitivity analyses and a value of information analysis were undertaken and the incremental net benefit was calculated.
Results
The mean hospital costs for the progesterone group, were £28,031.33 (SD 41,599.89) compared with £25,972.07 (SD 38,659.61) for placebo. The mean difference £2,059.25 was not statistically significant (p=0.33); the bootstrap cost difference was £2,334 (95% CI -5,023 to 9,142). The higher costs for the progesterone group were attributed to a greater need for neonatal care and maternal intensive care services.
The percentage of women with pre-term deliveries was 24.7% in the progesterone group versus 19.4% in the placebo group (OR 1.36, 95% CI 0.89 to 2.09).
The base case results did not change when the hospital ward costs were varied and the duration of neonatal hospitalisation in the placebo arm was varied. Bootstrapped analyses of the costs and effects indicated a 20% probability that progesterone was cost-effective at a willingness-to-pay threshold of £30,000 per pre-term birth prevented. At this threshold, there was a net loss to health services of £3,637 (95% CI 3,420 to 3,853). The expected value of perfect information was £1,033,400 based on the number of twin pregnancies per year in England and Wales.
: A net benefit analysis was used to synthesise the incremental costs and incremental effects, for a willingness-to-pay threshold. The results of the joint cost and effect uncertainty analyses were reported in detail, with a graph of the cost and effect pairings on the cost-effectiveness plane. Value of information analysis was used to estimate the value of conducting further research and the findings indicated that the costs of this research would not be justified. The authors provided a discussion of the limitations of their analysis.
Concluding remarks:
: The methods were satisfactory and the results were comprehensively reported. The authors' conclusions appear to be appropriate for the scope of their analysis.
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